Literature DB >> 2709671

Progression of renal insufficiency: role of blood pressure.

P C Brazy1, W W Stead, J F Fitzwilliam.   

Abstract

The effect of blood pressure on progression of renal insufficiency was examined in a large group of patients who eventually required dialysis. Out of 198 consecutive new chronic dialysis patients, 86 had sufficient data predialysis to determine rates of progression of renal insufficiency by reciprocal creatinine versus time plots. Average plasma creatinine at first contact was 3.8 +/- 0.2 mg/dl and at the time of dialysis was 11.4 +/- 0.4 mg/dl. Mean duration of follow-up was 33.4 +/- 2.5 months and the average rate of decline in reciprocal creatinine was -0.009 +/- 0.001 dl/mg month. Patients were stratified by average value of diastolic blood pressure measured in clinic. Patients in the lowest quartile had a rate of decline in reciprocal creatinine of -0.007 +/- 0.001 dl/mg month, which was slower than that of patients in the third and fourth quartiles, -0.010 +/- 0.001 and -0.011 +/- -0.002 dl/mg month, respectively (P less than 0.05). In individual patients, a mean diastolic BP of less than 90 mm Hg was associated with a rate of decline in reciprocal creatinine of -0.006 +/- 0.001 dl/mg month which was significantly less than the rate of -0.009 +/- 0.001 when the diastolic BP was greater than 90 mm Hg. Thus, in a large group of patients who have progressed to ESRD, there is an association between control of diastolic blood pressure and a slower rate of decline in renal function.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2709671     DOI: 10.1038/ki.1989.37

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  27 in total

Review 1.  ACE inhibitors and proteinuria.

Authors:  R T Gansevoort; D de Zeeuw; P E de Jong
Journal:  Pharm World Sci       Date:  1996-12

Review 2.  Recognition and management of IgA nephropathy.

Authors:  L S Ibels; A Z Gyory; R J Caterson; C A Pollock; J F Mahony; D A Waugh; S Coulshed
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

3.  Clinical problem solving based on the 1999 Canadian recommendations for the management of hypertension.

Authors:  R D Feldman; N R Campbell; P Larochelle
Journal:  CMAJ       Date:  1999       Impact factor: 8.262

4.  1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension.

Authors:  R D Feldman; N Campbell; P Larochelle; P Bolli; E D Burgess; S G Carruthers; J S Floras; R B Haynes; G Honos; F H Leenen; L A Leiter; A G Logan; M G Myers; J D Spence; K B Zarnke
Journal:  CMAJ       Date:  1999       Impact factor: 8.262

5.  Genetic susceptibility to hypertension-induced renal damage in the rat. Evidence based on kidney-specific genome transfer.

Authors:  P C Churchill; M C Churchill; A K Bidani; K A Griffin; M Picken; M Pravenec; V Kren; E St Lezin; J M Wang; N Wang; T W Kurtz
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

Review 6.  Treatment of lupus nephritis.

Authors:  Fayez F Hejaili; Louise M Moist; William F Clark
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Effect of antihypertensive drugs on glomerular hyperfiltration and renal haemodynamics. Comparison of captopril with nifedipine, metoprolol and celiprolol.

Authors:  J Böhler; A Becker; P Reetze-Bonorden; R Woitas; E Keller; P Schollmeyer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 8.  Angiotensin converting enzyme (ACE) inhibitors and renal function. A review of the current status.

Authors:  A L Kamper
Journal:  Drug Saf       Date:  1991 Sep-Oct       Impact factor: 5.606

Review 9.  Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of essential hypertension.

Authors:  R I Ogilvie; E D Burgess; J R Cusson; R D Feldman; L A Leiter; M G Myers
Journal:  CMAJ       Date:  1993-09-01       Impact factor: 8.262

Review 10.  Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.

Authors:  J Hoyer; K L Schulte; T Lenz
Journal:  Clin Pharmacokinet       Date:  1993-03       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.